These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23899277)

  • 1. The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate.
    Guedj J; Dahari H; Uprichard SL; Perelson AS
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5):397-9. PubMed ID: 23899277
    [No Abstract]   [Full Text] [Related]  

  • 2. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.
    Guedj J; Dahari H; Rong L; Sansone ND; Nettles RE; Cotler SJ; Layden TJ; Uprichard SL; Perelson AS
    Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3991-6. PubMed ID: 23431163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclatasvir: potential role in hepatitis C.
    Lee C
    Drug Des Devel Ther; 2013; 7():1223-33. PubMed ID: 24204123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-scale model for hepatitis C viral load kinetics under treatment with direct acting antivirals.
    Clausznitzer D; Harnisch J; Kaderali L
    Virus Res; 2016 Jun; 218():96-101. PubMed ID: 26409026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.
    Herbst DA; Reddy KR
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1337-46. PubMed ID: 23931586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.
    Plaza Z; Soriano V; Vispo E; del Mar Gonzalez M; Barreiro P; Seclén E; Poveda E
    Antivir Ther; 2012; 17(5):921-6. PubMed ID: 22436385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclatasvir for the treatment of chronic hepatitis C virus infection.
    Temesgen Z; Rizza SA
    Drugs Today (Barc); 2015 May; 51(5):277-88. PubMed ID: 26097901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4.
    McCormick AL; Wang L; Garcia-Diaz A; Macartney MJ; Webster DP; Haque T
    Antivir Ther; 2015; 20(1):81-5. PubMed ID: 24621453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
    Yoshimi S; Imamura M; Murakami E; Hiraga N; Tsuge M; Kawakami Y; Aikata H; Abe H; Hayes CN; Sasaki T; Ochi H; Chayama K
    J Med Virol; 2015 Nov; 87(11):1913-20. PubMed ID: 25954851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
    Hong CM; Liu CJ; Yeh SH; Chen PJ
    J Formos Med Assoc; 2017 Apr; 116(4):295-299. PubMed ID: 28034492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclatasvir for the treatment of chronic hepatitis C.
    Degasperi E; Aghemo A; Colombo M
    Expert Opin Pharmacother; 2015; 16(17):2679-88. PubMed ID: 26549010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.
    Wang C; Sun JH; O'Boyle DR; Nower P; Valera L; Roberts S; Fridell RA; Gao M
    Antimicrob Agents Chemother; 2013 May; 57(5):2054-65. PubMed ID: 23403428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection.
    McCormack PL
    Drugs; 2015 Apr; 75(5):515-24. PubMed ID: 25721433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.
    Zhou N; Han Z; Hartman-Neumann S; DeGray B; Ueland J; Vellucci V; Hernandez D; McPhee F
    J Antimicrob Chemother; 2016 Dec; 71(12):3495-3505. PubMed ID: 27605597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCV NS5A replication complex inhibitors.
    Gao M; O'Boyle DR; Roberts S
    Curr Opin Pharmacol; 2016 Oct; 30():151-157. PubMed ID: 27643675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NS5A inhibitors in the treatment of hepatitis C.
    Pawlotsky JM
    J Hepatol; 2013 Aug; 59(2):375-82. PubMed ID: 23567084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing.
    Bartolini B; Lionetti R; Giombini E; Sias C; Taibi C; Montalbano M; D'Offizi G; McPhee F; Hughes EA; Zhou N; Ippolito G; Garbuglia AR; Capobianchi MR
    J Clin Virol; 2015 May; 66():38-43. PubMed ID: 25866334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
    Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
    J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.